Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 12
Submit an article Journal homepage
182
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension

Steven G. Chrysant University of Oklahoma, Oklahoma City, OK, USACorrespondence[email protected]
,
Alexander V. Murray PharmQuest, Greensboro, NC, USA
,
Uta C. Hoppe Department of Internal Medicine III, University of Cologne, Cologne, Germany
,
Dan Dattani Prairie Clinical Research Group and University of Saskatchewan, Saskatoon, SK, Canada
,
Samir Patel Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Shannon Ritter Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
Jack Zhang Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
 show all
Pages 2841-2849 | Accepted 28 Sep 2010, Published online: 09 Nov 2010

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Steven G. Chrysant & George S. Chrysant. (2020) New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety 19:10, pages 1315-1327.
Read now
Michael B Hovater & Edgar A Jaimes. (2013) Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination. Integrated Blood Pressure Control 6, pages 59-67.
Read now
Christoph Axthelm, Christian Sieder, Franziska Meister, David Pittrow & Edelgard Kaiser. (2013) Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index. Journal of Drug Assessment 2:1, pages 1-10.
Read now
Fabio Angeli, Gianpaolo Reboldi, Giovanni Mazzotta, Cristina Poltronieri & Paolo Verdecchia. (2012) Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opinion on Drug Safety 11:4, pages 659-670.
Read now
Steven G. Chrysant. (2011) Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. Postgraduate Medicine 123:6, pages 21-31.
Read now

Articles from other publishers (8)

Nikolaos-Dimitrios Pantzaris, Evangelos Karanikolas, Konstantinos Tsiotsios & Dimitrios Velissaris. (2017) Renin Inhibition with Aliskiren: A Decade of Clinical Experience. Journal of Clinical Medicine 6:6, pages 61.
Crossref
Steven G. Chrysant & George S. Chrysant. (2014) Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. Current Hypertension Reports 17:1.
Crossref
Jamie J. Coleman & Anthony R. Cox. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 363 385 .
Joel M. Neutel & David H. G. Smith. (2013) Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action. Cardiovascular Therapeutics 31:5, pages 251-258.
Crossref
Thomas D. Giles, Thomas Alessi, Das Purkayastha & Dion Zappe. (2012) Comparative Efficacy of Aliskiren/Valsartan vs Valsartan in Nocturnal Dipper and Nondipper Hypertensive Patients: A Pooled Analysis. The Journal of Clinical Hypertension 14:5, pages 299-306.
Crossref
U. Zeymer, R. Dechend, E. Deeg, E. Kaiser, J. Senges, D. Pittrow & R. Schmieder. (2012) Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. International Journal of Clinical Practice 66:3, pages 251-261.
Crossref
Addison A. Taylor, Helmy Siragy & Shawna Nesbitt. (2011) Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety. The Journal of Clinical Hypertension 13:9, pages 677-686.
Crossref
E. O’Brien. (2011) Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. Journal of Internal Medicine 269:5, pages 478-495.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.